Allergan, Inc. (NYSE:AGN) was upgraded by research analysts at Goldman Sachs from a “buy” rating to a “conviction-buy” rating in a research report issued on Friday, The Fly reports.
A number of other research analysts also recently issued reports on the company. Mizuho dropped their price target on Allergan from $250.00 to $232.00 and set a “neutral” rating on the stock in a research note on Friday. Citigroup Inc. reiterated a “buy” rating on shares of Allergan in a research note on Wednesday. Piper Jaffray reiterated a “cautious” rating on shares of Allergan in a research note on Wednesday. Deutsche Bank reiterated a “buy” rating on shares of Allergan in a research note on Monday, April 18th. Finally, Guggenheim assumed coverage on Allergan in a research note on Monday, April 18th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Allergan has an average rating of “Buy” and an average target price of $317.57.
Source: American Banking and Market News